Immediate Impact
3 by Nobel laureates 66 standout
Citing Papers
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Marco Iafolla being referenced
Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody.
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Marco Iafolla | 172 | 209 | 96 | 137 | 37 | 428 | |
| Sarah Abou Alaiwi | 193 | 229 | 87 | 117 | 44 | 402 | |
| Jindřich Kopecký | 161 | 216 | 78 | 102 | 49 | 450 | |
| Giulia Orsi | 143 | 212 | 111 | 164 | 34 | 490 | |
| Dilara Akhoundova | 110 | 229 | 104 | 134 | 44 | 379 | |
| Robert Alter | 195 | 253 | 86 | 124 | 29 | 446 | |
| Kyrillus S. Shohdy | 201 | 193 | 108 | 85 | 38 | 419 | |
| Jane C. Wright | 91 | 210 | 83 | 142 | 42 | 484 | |
| Elisa Capizzi | 164 | 201 | 119 | 181 | 28 | 464 | |
| Karel Cwiertka | 120 | 242 | 106 | 113 | 45 | 425 | |
| Yan Wu | 140 | 184 | 48 | 107 | 30 | 425 |
All Works
Login with ORCID to disown or claim papers
Loading papers...